HIV prevention drug could reduce number of cases globally but USAID cuts prevent access, say experts

Summary

Injectable PrEP drug holds promise but investment in HIV prevention has declined dramatically worldwide Sign up for the Breaking News US newsletter email New innovations in HIV prevention could dramatically reduce the number of new HIV cases around the globe, but US foreign aid cuts will mean that those that most need the new medication will be unable to access it, according to experts at the Aids 2026 Conference in Rio de Janeiro, Brazil . One year ago, the World Health Organization recommended that governments around the world prioritize expanded access to lenacapavir, an injectable version of the HIV prevention medication PrEP that requires only two injections annually. PrEP, which also comes in the form of daily oral medications and bimonthly injections, is 99% effective in preventing sexually transmitted HIV for people who take it consistently. Continue reading...

News Radar provides aggregated summaries. Full content and copyright remain with the original publisher.